E230008N13Rik Inhibitors
The chemical class referred to as E230008N13Rik Inhibitors encompasses a diverse group of compounds that have the potential to inhibit E230008N13Rik through various mechanisms. These inhibitors target different signaling pathways involved in E230008N13Rik activation and function. PD173074, BGJ398, and Dovitinib are FGFR inhibitors that can potentially inhibit E230008N13Rik by blocking the FGFR signaling pathway. Inhibition of FGFR may disrupt downstream events crucial for E230008N13Rik activation, negatively impacting its functionality.
PI-103, TGX-221, and BYL719, as inhibitors of the PI3K/AKT pathway, may inhibit E230008N13Rik by disrupting this signaling pathway. Inhibition of PI3K can lead to downstream effects that negatively impact E230008N13Rik activation, contributing to its functional suppression. BAY 61-3606, R406, and GDC-0994 are inhibitors targeting the Syk signaling pathway, potentially inhibiting E230008N13Rik by interfering with Syk-mediated signaling pathways. SCH772984, AZD6244, and GSK1120212 act as inhibitors of the MEK/ERK pathway, potentially inhibiting E230008N13Rik by blocking this signaling cascade. Inhibition of MEK can lead to downstream effects that negatively impact E230008N13Rik activation, contributing to its functional suppression.
The diversity in mechanisms displayed by E230008N13Rik Inhibitors highlights the intricate regulation of E230008N13Rik and the interconnectedness of cellular pathways influencing its activation. Researchers can employ these inhibitors to unravel the complex regulatory networks associated with E230008N13Rik and gain insights into potential avenues for modulating its function in cellular processes.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $46.00 $140.00 $680.00 | 16 | |
PD173074, a FGFR inhibitor, may inhibit E230008N13Rik by blocking the FGFR signaling pathway. Inhibition of FGFR can disrupt downstream events crucial for E230008N13Rik activation, negatively impacting its functionality. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $32.00 $128.00 | 3 | |
PI-103, a dual PI3K/mTOR inhibitor, can potentially inhibit E230008N13Rik by disrupting the PI3K/mTOR signaling pathway. This interference may lead to downstream effects that negatively impact E230008N13Rik activation and functionality. | ||||||
Syk Inhibitor IV, BAY 61-3606 HCl | 732983-37-8 | sc-202351 | 2 mg | $321.00 | 25 | |
BAY 61-3606, a Syk inhibitor, may inhibit E230008N13Rik by interfering with Syk-mediated signaling pathways. Disruption of Syk signaling can lead to downstream effects that negatively impact E230008N13Rik activation and functionality. | ||||||
SCH772984 | 942183-80-4 | sc-473205 | 5 mg | $363.00 | 5 | |
SCH772984, an ERK inhibitor, can inhibit E230008N13Rik by blocking the MEK/ERK signaling pathway. Inhibition of ERK signaling may lead to downstream effects that negatively impact E230008N13Rik activation and contribute to its functional suppression. | ||||||
GDC0994 | 1453848-26-4 | sc-507297 | 10 mg | $130.00 | ||
GDC-0994, a ERK inhibitor, can potentially inhibit E230008N13Rik by blocking the MEK/ERK signaling pathway. This interference may lead to downstream effects that negatively impact E230008N13Rik activation and contribute to its functional suppression. | ||||||
PI 3-Kβ Inhibitor VI, TGX-221 | 663619-89-4 | sc-203190 | 1 mg | $437.00 | ||
TGX-221, a PI3K inhibitor, may inhibit E230008N13Rik by disrupting the PI3K/AKT signaling pathway. Inhibition of PI3K can lead to downstream effects that negatively impact E230008N13Rik activation, contributing to its functional suppression. | ||||||
BGJ398 | 872511-34-7 | sc-364430 sc-364430A sc-364430B sc-364430C | 5 mg 10 mg 50 mg 100 mg | $212.00 $247.00 $582.00 $989.00 | 4 | |
BGJ398, a FGFR inhibitor, can potentially inhibit E230008N13Rik by blocking the FGFR signaling pathway. Inhibition of FGFR can disrupt downstream events crucial for E230008N13Rik activation, negatively impacting its functionality. | ||||||
R406 | 841290-81-1 | sc-364595 sc-364595A | 2 mg 10 mg | $160.00 $370.00 | 16 | |
R406, a Syk inhibitor, may inhibit E230008N13Rik by interfering with Syk-mediated signaling pathways. Disruption of Syk signaling can lead to downstream effects that negatively impact E230008N13Rik activation and functionality. | ||||||
BYL719 | 1217486-61-7 | sc-391001 sc-391001A sc-391001B sc-391001C sc-391001D sc-391001E | 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $383.00 $585.00 $740.00 $1169.00 $4902.00 $9186.00 | 2 | |
BYL719, a PI3Kα inhibitor, may inhibit E230008N13Rik by disrupting the PI3K/AKT signaling pathway. Inhibition of PI3K can lead to downstream effects that negatively impact E230008N13Rik activation, contributing to its functional suppression. | ||||||
Dovitinib, Free Base | 405169-16-6 | sc-396771 sc-396771A | 10 mg 25 mg | $170.00 $350.00 | ||
Dovitinib, a FGFR inhibitor, can potentially inhibit E230008N13Rik by blocking the FGFR signaling pathway. Inhibition of FGFR can disrupt downstream events crucial for E230008N13Rik activation, negatively impacting its functionality. | ||||||